---
figid: PMC3388555__bjc2012145f6
figtitle: Association between sorafenib and the MAPK cascade
organisms:
- Homo sapiens
- Mus musculus
- Armoracia rusticana
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
- Arabidopsis thaliana
- Caenorhabditis elegans
pmcid: PMC3388555
filename: bjc2012145f6.jpg
figlink: /pmc/articles/PMC3388555/figure/fig6/
number: F6
caption: Association between sorafenib and the MAPK cascade. Sorafenib inhibits the
  Raf/ERK signalling pathway but not the JNK signalling pathway. The therapeutic efficacy
  of sorafenib would be limited when JNK is activated in HCCs. Treatment with sorafenib
  in combination with a JNK inhibitor might open promising therapeutic perspectives.
papertitle: Activation of JNK and high expression level of CD133 predict a poor response
  to sorafenib in hepatocellular carcinoma.
reftext: S Hagiwara, et al. Br J Cancer. 2012 Jun 5;106(12):1997-2003.
year: '2012'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9367052
figid_alias: PMC3388555__F6
figtype: Figure
redirect_from: /figures/PMC3388555__F6
ndex: 52337ba3-def9-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3388555__bjc2012145f6.html
  '@type': Dataset
  description: Association between sorafenib and the MAPK cascade. Sorafenib inhibits
    the Raf/ERK signalling pathway but not the JNK signalling pathway. The therapeutic
    efficacy of sorafenib would be limited when JNK is activated in HCCs. Treatment
    with sorafenib in combination with a JNK inhibitor might open promising therapeutic
    perspectives.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ras
  - Hras
  - Kras
  - Rem1
  - Map2k1
  - Map3k1
  - Map3k3
  - Map3k2
  - Zhx2
  - Map2k2
  - Map2k4
  - Map2k7
  - Mapk3
  - Mapk1
  - Mapk8
  - Mapk10
  - Mapk9
  - Kcnh8
  - Ephb1
  - Atp7a
  - Jun
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - KRAS
  - HRAS
  - NRAS
  - MAP3K1
  - MAP3K3
  - MAP3K2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K1
  - MAP2K2
  - MAP2K4
  - MAP2K7
  - MAPK3
  - MAPK1
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - EPHB1
  - KCNH8
  - OGDH
  - ATP7A
  - JUN
  - Ras64B
  - Ras85D
  - wnd
  - Mekk1
  - Raf
  - Dsor1
  - hep
  - Mkk4
  - rl
  - MKP-4
  - p38b
  - Elk
  - lok
  - Jra
  - MEKK1
  - MEKK3
  - MAPKKK9
  - MEK1
  - MKK4
  - MKK7
  - mekk-3
  - mek-1
  - mek-2
  - mkk-4
  - jnk-1
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
---
